News IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Market Closed - Nasdaq Stockholm Other stock markets 16:29:58 03/05/2024 BST			5-day change	1st Jan Change
10.95 ^SEK	-1.79%		+6.83%	+46.00%

03-22	IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	CI
03-19	IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IRLAB publishes Annual Report for 2023	04-29	AQ
IRLAB to present at Redeye Investor Forum	04-16	AQ
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	03-25	AQ
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	03-22	CI
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	03-22	AQ
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	03-19	CI
IRLAB Therapeutics : mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis	03-19	PU
IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis	03-19	AQ
IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG	02-29	AQ
IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7	02-28	AQ
IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases	02-27	AQ
IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam	02-22	AQ
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	02-22	CI
IRLAB's pioneering Phase IIb study with pirepemat, React-PD, provides new insights in specific Parkinson's patient population and enables a data driven prediction of study timelines	02-07	AQ
Transcript : IRLAB Therapeutics AB, 2023 Earnings Call, Feb 07, 2024	02-07
IRLAB publishes year-end report for the period January-December 2023	02-07	AQ
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-07	CI
IRLAB’s pioneering Phase IIb study with pirepemat – React-PD – provides new insights in specific Parkinson’s patient population and enables a data driven prediction of study timelines	02-06	AQ
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	02-06	CI
IRLAB, Invitation to the Year-end Report 2023 presentation and webcast	02-01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Summary

Filters